Compounds > 1-formylisoquinoline thiosemicarbazone
Page last updated: 2024-12-11
1-formylisoquinoline thiosemicarbazone
Description
## 1-Formylisoquinoline Thiosemicarbazone (1-FIQ)
1-Formylisoquinoline thiosemicarbazone (1-FIQ) is a **heterocyclic compound** with a **thiosemicarbazone** functional group attached to an isoquinoline ring. Its structure contains both **nitrogen** and **sulfur** atoms, making it a potential **chelating agent** for various metals.
**Importance in Research:**
1-FIQ has gained significant attention in research due to its promising biological activities, particularly:
* **Anti-cancer properties:** 1-FIQ exhibits significant **anti-proliferative** and **anti-tumor** activities against various cancer cell lines, including leukemia, lung, breast, and prostate cancers. Its mechanism of action involves inhibiting the growth of cancer cells by **inducing apoptosis** and **arresting cell cycle progression**.
* **Anti-viral properties:** Studies have shown that 1-FIQ demonstrates **antiviral activity** against a wide range of viruses, including **HIV**, **influenza**, and **herpes simplex virus**. It achieves this by inhibiting the replication of these viruses.
* **Anti-parasitic properties:** 1-FIQ has shown **anti-parasitic activity** against various protozoa, such as **malaria** and **toxoplasmosis**.
* **Anti-inflammatory properties:** 1-FIQ has been shown to possess **anti-inflammatory** properties, likely due to its ability to **inhibit the production of inflammatory mediators**.
**Research Directions:**
Current research efforts are focused on:
* **Understanding the mechanism of action** of 1-FIQ in different biological systems to enhance its effectiveness and minimize potential side effects.
* **Developing novel derivatives** of 1-FIQ with improved potency and selectivity for specific therapeutic targets.
* **Evaluating the potential of 1-FIQ** as a therapeutic agent for various diseases, including cancer, viral infections, and parasitic infections.
* **Exploring the potential of 1-FIQ** as a lead compound for the development of new drugs with improved efficacy and safety profiles.
**Overall, 1-FIQ represents a promising therapeutic candidate with a wide range of potential applications in various medical fields. Further research on its pharmacological properties and clinical trials are necessary to fully realize its therapeutic potential.**
1-formylisoquinoline thiosemicarbazone: structure; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (13)
Synonym |
isoquinaldehyde thiosemicarbazone |
nsc 92188 |
ai3-51873 |
2-(1-isoquinolinylmethylene)hydrazinecarbothioamide |
[(z)-1-isoquinolylmethyleneamino]thiourea |
1-formylisoquinoline thiosemicarbazone |
isoquinaldaldehyde, thiosemicarbazone |
61043-13-8 |
mls002702043 , |
nsc-162700 |
nsc162700 |
[(z)-isoquinolin-1-ylmethylideneamino]thiourea |
CHEMBL1976175 |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 6 (85.71) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.21
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.21 (24.57) | Research Supply Index | 2.08 (2.92) | Research Growth Index | 4.29 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (42.86%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (57.14%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |